药物治疗女性高脂血症的药物治疗
Judith M E Walsh1, Michael Pignone
1Division of General Internal Medicine and Department of Epidemiology and Biostatistics, University of California, San Francisco, USA. jmwalsh@itsa.ucsf.edu
JAMA
|May 13, 2004
概括
降脂药在没有心脏病的女性中没有显著减少心血管事件. 然而,对于患有心血管疾病的女性来说,这些药物有效地降低了死亡率并预防了心血管疾病的发生.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 在过去的冠状动脉心脏病 (CHD) 降脂药物试验中进行了有限的性别特定分析.
- 需要对预防心血管疾病的妇女高脂血症治疗的证据综合.
研究的目的:
- 评估和综合关于药物治疗高脂血症的证据,以预防女性心脏病.
- 对药物治疗对妇女死亡率的影响进行元分析.
主要方法:
- 搜索了MEDLINE,柯克伦数据库和有效性审查摘要 (1966-2003) 数据库.
- 包括持续时间 >= 1 年的研究,临床结果和性别特定的结果.
- 使用随机效应模型计算总结相对风险 (RRs).
主要成果:
- 在没有心血管疾病的女性 (11,435人) 中,降低脂质并没有降低总死亡率,心血管疾病死亡率,心肌梗塞或再血管.
- 在患有心血管疾病的女性 (8,272) 中,降低脂质可以降低心血管疾病的死亡率,非致命的心肌梗塞,再血管化和总体心血管疾病事件.
结论:
- 降低脂质并不会影响没有心血管疾病的女性的总死亡率或心血管疾病死亡率;减少心血管疾病事件的证据是不确定的.
- 对于已确诊的心血管疾病的妇女来说,高脂血症治疗有效地减少了心血管疾病的发生,死亡率,心肌梗塞和再血管化,但不是总死亡率.
更多相关视频
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
03:05Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
Published on: November 21, 2025
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...